A novel tumor-homing TRAIL variant eradicates tumor xenografts of refractory colorectal cancer cells in combination with tumor cell-targeted photodynamic therapy

References

• Abrahamse H, Houreld NN. (2019). Genetic aberrations associated with photodynamic therapy in colorectal cancer cells. IJMS 20:1698.
   Google Scholar
• Alzeibak R, Mishchenko TA, Shilyagina NY, et al. (2021). Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer 9:e001926.
   PubMed Web of Science ®Google Scholar
• Cao D, Qin S, Mu Y, Zhong M. (2017). The role of MRP1 in the multidrug resistance of colorectal cancer. Oncol Lett 13:2471–6.
   PubMed Web of Science ®Google Scholar
• Deng D, Shah K. (2020). TRAIL of hope meeting resistance in cancer. Trends Cancer 6:989–1001.
   PubMed Web of Science ®Google Scholar
• Di X, Zhang G, Zhang Y, et al. (2013). Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 4:1349–64.
   PubMedGoogle Scholar
• Dianat-Moghadam H, Heidarifard M, Mahari A, et al. (2020). TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res 155:104716.
   PubMed Web of Science ®Google Scholar
• Dysart JS, Patterson MS. (2005). Characterization of photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro. Phys Med Biol 50:2597–616.
   PubMed Web of Science ®Google Scholar
• Fulda S. (2015). Safety and tolerability of TRAIL receptor agonists in cancer treatment. Eur J Clin Pharmacol 71:525–7.
   PubMed Web of Science ®Google Scholar
• Gong J, Han J, He J, et al. (2017). Paired related homeobox protein 1 regulates PDGF-induced chemotaxis of hepatic stellate cells in liver fibrosis. Lab Invest 97:1020–32.
   PubMed Web of Science ®Google Scholar
• Gustavsson B, Carlsson G, Machover D, et al. (2015). A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 14:1–10.
   PubMed Web of Science ®Google Scholar
• Huang Y, Li X, Sha H, et al. (2017). sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment. Sci Rep 7:579.
   PubMed Web of Science ®Google Scholar
• Johansson A, Hamzah J, Payne CJ, Ganss R. (2012). Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 109:7841–6.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Laakkonen P, Bernasconi M, et al. (2003). Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4:1698–403.
   Web of Science ®Google Scholar
• LeBlanc HN, Ashkenazi A. (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66–75.
   PubMed Web of Science ®Google Scholar
• Li R, Yang H, Jia D, et al. (2016). Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J Control Release 228:96–106.
   PubMed Web of Science ®Google Scholar
• Manghnani PN, Wu W, Xu S, et al. (2018). Visualizing photodynamic therapy in transgenic zebrafish using organic nanoparticles with aggregation-induced emission. Nanomicro Lett 10:61.
   PubMed Web of Science ®Google Scholar
• McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. (2017). Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem 24:1537–57.
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, et al. (2006). Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26:7046–55.
   PubMed Web of Science ®Google Scholar
• Micsik T, Lőrincz A, Mersich T, et al. (2015). Decreased functional activity of multidrug resistance protein in primary colorectal cancer. Diagn Pathol 10:26.
   PubMed Web of Science ®Google Scholar
• Mitsunaga M, Ogawa M, Kosaka N, et al. (2011). Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 17:1685–91.
   PubMed Web of Science ®Google Scholar
• Moan J, Berg K. (1991). The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53:549–53.
   PubMed Web of Science ®Google Scholar
• Möller Y, Siegemund M, Beyes S, et al. (2014). EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells. PLOS One 9:e107165.
   PubMed Web of Science ®Google Scholar
• Razeghian E, Suksatan W, Sulaiman Rahman H, et al. (2021). Harnessing TRAIL-induced apoptosis pathway for cancer immunotherapy and associated challenges. Front Immunol 12:699746.
   PubMed Web of Science ®Google Scholar
• She T, Shi Q, Li Z, et al. (2021). Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer. Theranostics 11:4281–97.
   PubMed Web of Science ®Google Scholar
• Shi Q, Tao Z, Yang H, et al. (2017). PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer. Drug Deliv 24:1818–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding Sauer A, et al. (2020). Colorectal cancer statistics, 2020. CA A Cancer J Clin 70:145–64.
   PubMed Web of Science ®Google Scholar
• Snajdauf M, Havlova K, Vachtenheim J Jr, et al. (2021). The TRAIL in the treatment of human cancer: an update on clinical trials. Front Mol Biosci 8:628332.
   PubMed Web of Science ®Google Scholar
• Stolfi C, Pallone F, Monteleone G. (2012). Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int J Mol Sci 13:7886–901.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–49.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. (2017). GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98–W102.
   PubMed Web of Science ®Google Scholar
• Tao Z, Yang H, Shi Q, et al. (2017). Targeted delivery to tumor-associated pericytes via an affibody with high affinity for PDGFRβ enhances the in vivo antitumor effects of human TRAIL. Theranostics 7:2261–76.
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Messersmith WA, Peddi PF, et al. (2013). A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer 12:248–54.
   PubMed Web of Science ®Google Scholar
• Wong RS. (2011). Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30:87.
   PubMed Web of Science ®Google Scholar
• Wong SHM, Kong WY, Fang CM, et al. (2019). The TRAIL to cancer therapy: hindrances and potential solutions. Crit Rev Oncol Hematol 143:81–94.
   PubMed Web of Science ®Google Scholar
• Xie YH, Chen YX, Fang JY. (2020). Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 5:22.
   PubMed Web of Science ®Google Scholar
• Xue Y, Ma C, Hanna I, Pan G. (2019). Intestinal transporter-associated drug absorption and toxicity. Adv Exp Med Biol 1141:361–405.
   PubMed Web of Science ®Google Scholar
• Yang H, Feng Y, Cai H, et al. (2018). Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects. Theranostics 8:2459–76.
   PubMed Web of Science ®Google Scholar